Literature DB >> 12634967

Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET.

Susanne Nikolaus1, Rolf Larisch, Markus Beu, Farhad Forutan, Henning Vosberg, Hans-Wilhelm Müller-Gärtner.   

Abstract

Unilateral destruction of the substantia nigra by local application of 6-hydroxydopamine (6-OHDA) serves as an animal model for Parkinson's disease. In this study, the changes in neostriatal dopamine D(2) receptor density were investigated with a small animal positron emission tomograph (PET) before and after 6-OHDA lesion. PET scans were performed in 14 rats after injection of the D(2) receptor radioligand [(18)F] N-methylbenperidol. After the first scan (day 0), nigrostriatal pathways were lesioned by unilateral injections of 6-OHDA. Further PET scans were performed on days 2 and 14 post-lesion. For both striata, B(max) values were determined from saturation binding curves with non-linear regression analysis. In the striatum ipsilateral to the lesion, B(max) initially amounted to 19.3+/-1. 9 fmol/mg (mean+/-SD) and increased to 19.7+/-2.2 and 29.9+/-5.7 fmol/mg on days 2 and 14 post-lesion, respectively. Contralateral B(max) values increased from 19.2+/-2 fmol/mg prior to the lesion to 21.2+/-2.9 and 28.6+/-5.7 fmol/mg on days 2 and 14, respectively. On day 14, the ipsilateral saturation binding curve differed from the ipsilateral pre-lesion curve (P=0.04; F test). When the contralateral pre-lesion saturation binding curve was compared with the contralateral post-lesion curve on day 14, a P value of 0.08 was obtained. This first serial in vivo imaging study of 6-OHDA-lesioned rats showed a time-dependent increase in striatal D(2) receptor density on both sides, the increase being more pronounced ipsilateral to the lesion. This result implies that compensatory mechanisms in the intact hemisphere contribute to regenerative processes following nigrostriatal dopaminergic denervation. Overall, our findings show the feasibility of repetitive in vivo studies of striatal receptor density with a small animal tomograph. Moreover, the applied in vivo saturation binding technique provides a versatile method for the quantification of time-dependent changes in the concentration of receptor binding sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12634967     DOI: 10.1007/s00259-002-1056-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  22 in total

Review 1.  Molecular imaging of small animals with dedicated PET tomographs.

Authors:  Arion F Chatziioannou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2001-11-22       Impact factor: 9.236

2.  Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET.

Authors:  T V Nguyen; A L Brownell; Y C Iris Chen; E Livni; J T Coyle; B R Rosen; F Cavagna; B G Jenkins
Journal:  Synapse       Date:  2000-04       Impact factor: 2.562

Review 3.  Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae.

Authors:  R K Schwarting; J P Huston
Journal:  Prog Neurobiol       Date:  1996-06       Impact factor: 11.685

4.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

5.  Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.

Authors:  S Chalon; P Emond; S Bodard; M P Vilar; C Thiercelin; J C Besnard; D Guilloteau
Journal:  Synapse       Date:  1999-02       Impact factor: 2.562

6.  Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.

Authors:  K A Neve; C A Altar; C A Wong; J F Marshall
Journal:  Brain Res       Date:  1984-06-04       Impact factor: 3.252

7.  Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes.

Authors:  R K Mishra; A M Marshall; S L Varmuza
Journal:  Brain Res       Date:  1980-10-27       Impact factor: 3.252

8.  Plasticity of neostriatal dopamine receptors after nigrostriatal injury: relationship to recovery of sensorimotor functions and behavioral supersensitivity.

Authors:  K A Neve; M R Kozlowski; J F Marshall
Journal:  Brain Res       Date:  1982-07-22       Impact factor: 3.252

9.  Changes of the striatal 3H-spiperone binding 3-6 weeks after nigrostriatal denervation and after two years.

Authors:  B Guerin; C Silice; P Mouchet; C Feuerstein; P Demenge
Journal:  Life Sci       Date:  1985-09-09       Impact factor: 5.037

10.  Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.

Authors:  H S Pan; J B Penney; A B Young
Journal:  J Neurochem       Date:  1985-11       Impact factor: 5.372

View more
  14 in total

Review 1.  Techniques for brain imaging in vivo.

Authors:  Monica Garcia-Alloza; Brian J Bacskai
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

2.  Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  J K Morris; H Zhang; A A Gupte; G L Bomhoff; J A Stanford; P C Geiger
Journal:  Brain Res       Date:  2008-09-11       Impact factor: 3.252

Review 3.  Quantitative Rodent Brain Receptor Imaging.

Authors:  Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

4.  Transient parkinsonism after unilateral midbrain stroke: a compensatory intervention from the healthy side?

Authors:  Tommaso Schirinzi; Agostino Chiaravalloti; Alessandro Davoli; Mariangela Pierantozzi; Giuseppe Sancesario
Journal:  Neurol Sci       Date:  2014-05-23       Impact factor: 3.307

5.  Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism.

Authors:  Cindy Casteels; Emili Martinez; Guy Bormans; Lluïsa Camon; Núria de Vera; Veerle Baekelandt; Anna M Planas; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-03       Impact factor: 9.236

6.  Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease.

Authors:  Ho-Joo Lee; Richard P Bazinet; Stanley I Rapoport; Abesh Kumar Bhattacharjee
Journal:  Neurochem Res       Date:  2009-12-08       Impact factor: 3.996

7.  Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging.

Authors:  Wynne K Schiffer; David L Alexoff; Colleen Shea; Jean Logan; Stephen L Dewey
Journal:  J Neurosci Methods       Date:  2004-12-08       Impact factor: 2.390

8.  Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425.

Authors:  Abesh Kumar Bhattacharjee; Lixin Lang; Orit Jacobson; Bidhan Shinkre; Ying Ma; Gang Niu; William C Trenkle; Kenneth A Jacobson; Xiaoyuan Chen; Dale O Kiesewetter
Journal:  Nucl Med Biol       Date:  2011-03-30       Impact factor: 2.408

9.  Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability?

Authors:  Martin T Woodlee; Jacqueline R Kane; Jitsen Chang; Lawrence K Cormack; Timothy Schallert
Journal:  Exp Neurol       Date:  2008-03-18       Impact factor: 5.330

10.  In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease.

Authors:  Abesh Kumar Bhattacharjee; Lindsey M Meister; Lisa Chang; Richard P Bazinet; Laura White; Stanley I Rapoport
Journal:  Neuroimage       Date:  2007-06-27       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.